Journal of Modern OncologyJournal of Modern OncologyСовременная онкология1815-14341815-1442LLC Obyedinennaya Redaktsiya26931ArticlesСтатьиResearch ArticleThe role of tamoxifen in the therapy of metastatic ovarian cancerРоль тамоксифена в терапии метастатического рака яичникаDavidenkoI SДавиденкоИрина Сергеевна

д-р мед. наук, зав. отд-нием химиотерапии

KazantsevaM VКазанцеваМаргарита Викторовна

канд. мед. наук, глав. врач ГБУЗ КОД №1

PorhanovaN VПорхановаНаталья Владимировна

д-р мед. наук, зав. отд-нием онкогинекологии

OhanyanM RОганянМариетта Рафаеловна

врач-ординатор отд-ния онкогинекологии

ГБУЗ Клинический онкологический диспансер №1 Минздрава Краснодарского края15032014161VOL 16, NO1 (2014)ТОМ 16, №1 (2014)262909042020Copyright ©; 2014, Consilium MedicumCopyright ©; 2014, ООО "Консилиум Медикум"2014Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc/4.0https://modernonco.orscience.ru/1815-1434/article/view/26931

Ovarian cancer is one of the most widely spread among women malignant tumors. Despite high sensitivity to anti-cancer chemotherapy (responses are awaited from more than 80% of women, receiving standard therapy with platinum and paclitaxel) recurrence of the disease takes place and the tumor becomes resistant to further therapy. Thus, it becomes necessary to invent new types of non-toxic therapy, taking into consideration biological qualities of the tumor. Tamoxifen therapy has efficacy in previously intensively treated patients with metastatic ovarian cancer, and it has low toxicity as well.

Рак яичника - одна из наиболее часто встречающихся злокачественных опухолей у женщин. Несмотря на высокую чувствительность к противоопухолевой химиотерапии (ремиссия отмечается более чем у 80% пациенток, получающих в качестве 1-й линии стандартную терапию препаратами платины и паклитаксела), наступают рецидив заболевания и резистентность к дальнейшим видам терапии. Таким образом, возникает необходимость разработки новых нетоксичных методов терапии с учетом биологических свойств опухоли. Тамоксифен улучшает результаты у интенсивно предлеченных больных с метастатическим раком яичника и обладает при этом невысокой токсичностью.

metastatic ovarian canceranti-oestrogen therapytamoxifenметастатический рак яичникаантиэстрогенная терапиятамоксифенJemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59 (4): 225-49.Eisenkop S.M, Friedman R.L, Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998; 69 (2): 103-8.Armstrong D.K, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354 (1): 34-43.Markman M, Bookman M.A. Second - line treatment of ovarian cancer. Oncologist 2000; 5 (1): 26-35.Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. 2005; 365 (9453): 60-2.Jakesz R, Jonat W, Gnant M et al. ABCSG and the GABG. Switching of postmenopausal women with endocrine - responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366 (9484): 455-62.Schwartz P.E, Keating G, Mac Lusky N et al. Tamoxifen therapy for advanced ovarian cancer. Obstet Gynecol 1982; 59 (5): 583-8.Shirey D.R, Kavanagh J.J.Jr, Gershenson D.M et al. Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol 1985; 66 (4): 575-8.Slevin M.L, Harvey V.J, Osborne R.J et al. A phase II study of tamoxifen in ovarian cancer. Eur J Cancer Clin Oncol 1986; 22 (3): 309-12.Osborne R.J, Malik S.T, Slevin M.L et al. Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule. Br J Cancer 1988; 57 (1): 115-6.Ahlgren J.D, Ellison N.M, Gottlieb R.J et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 1993; 11 (10): 1957-68.Van der Vange N, Greggi S, Burger C.W et al. Experience with hormonal therapy in advanced epithelial ovarian cancer. Acta Oncol 1995; 34 (6): 813-20.Van Der Velden J, Gitsch G, Wain G.V et al. Tamoxifen in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 1995; 5 (4): 301-5.Marth C, Sorheim N, Kaern J, Trope C. Tamoxifen in the treatment of recurrent ovarian carcinoma. Int J Gynecol Cancer 1997; 7: 256-61.Markman M, Webster K, Zanotti K et al. Use of tamoxifen in asymptomatic patients with recurrent small - volume ovarian cancer. Gynecol Oncol 2004; 93 (2): 390-3.Karagol H, Saip P, Uygun K et al. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer. Med Oncol 2007; 24 (1): 39-43.Markman M, Webster K, Zanotti K et al. Phase 2 trial of carboplatin plus tamoxifen in platinum - resistant ovarian cancer and primary carcinoma of the peritoneum. Gynecol Oncol 2004; 94 (2): 404-8.Schwartz P.E, Chambers J.T, Kohorn E.I et al. Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial. Cancer 1989; 63 (6): 1074-8.Millward M.J, Cantwell B.M, Lien E.A et al. Intermittent high - dose tamoxifen as a potential modifier of multidrug resistance. Eur J Cancer 1992; 28A (4-5): 805-10.Benedetti P.P, Greggi S, Amoroso M et al. A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum - based chemotherapy: results of a Phase II study. Int J Gynecol Cancer 2001; 11 (6): 438-44.